Mark Ragosa - 16 Mar 2022 Form 4 Insider Report for Kiniksa Pharmaceuticals, Ltd. (KNSA)

Role: Chief Financial Officer
Signature: /s/ Madelyn Zeylikman, Attorney-in-Fact for Mark Ragosa
Issuer symbol: KNSA
Transactions as of: 16 Mar 2022
Net transactions value: -$3,069
Form type: 4
Filing time: 18 Mar 2022, 16:38:03 UTC
Previous filing: 07 Sep 2021
Next filing: 23 Mar 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KNSA	Class A Common Share	Options Exercise		+872	+28%		3,979	16 Mar 2022	Direct	F1
transaction	KNSA	Class A Common Share	Tax liability	$3,069	-303	-7.6%	$10.13	3,676	16 Mar 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KNSA	Restricted Share Unit	Options Exercise	$0	-872	-25%	$0.000000	2,616	16 Mar 2022	Class A Common Share	872		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.
F2	The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 16, 2021.